The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol
International Journal of Immunopathology and Pharmacology · 2024-01 · 38
DOI: 10.1177/03946320241284089 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift International Journal of Immunopathology and Pharmacology, online erschienen am 20.09.2024. Verfasst von Erkan Topkan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey. Hauptthemen laut MEDLINE: Glioblastoma, Inflammation, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Systemic inflammation can significantly impact gliomas’ onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrutinized concerning their prognostic value in GBM patients.
Objective
We sought to investigate whether the recently introduced Global Immune-Nutrition-Inflammation Index (GINI) holds prognostic significance for GBM patients treated with the standard Stupp protocol.
Methods
We retrospectively analyzed the data from a cohort of newly diagnosed GBM patients receiving the standard Stupp regimen using the propensity score-matching methodology. The GINI was computed using the original formula: GINI = [(C-reactive protein × Monocytes × Platelets × Neutrophils) ÷ (Albumin × Lymphocytes)]. We employed receiver operating characteristic (ROC) curve analysis to identify the optimal cutoff values for GINI, which could help distinguish between different survival outcomes. The primary and secondary objectives were the differences in overall survival (OS) and progression-free survival (PFS) between the GINI groups.
Results
The optimal GINI cutoff value was 1350. Out of 294 eligible patients, 211 were PSM-matched: GINI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey.
- Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey.
- Department of Radiation Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
- Clinics of Medical Oncology, Adana Medical Park Hospital, adana, Turkey.
- Clinics of Medical Oncology, Adana Medical Park Hospital, Istinye University, Istanbul, Turkey.
- Department of Radiation Oncology, Medical Faculty, Bahcesehir University, Istanbul, Turkey.
ORCID-Profile: Erkan Topkan, Duriye Öztürk
Zitieren
APA
Topkan, E., Kilic Durankus, N., Senyurek, S., Öztürk, D., Besen, A. A., Mertsoylu, H., Pehlivan, B., & Selek, U. (2024). The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol. International Journal of Immunopathology and Pharmacology, 38. https://doi.org/10.1177/03946320241284089
Vancouver
Topkan E, Kilic Durankus N, Senyurek S, Öztürk D, Besen AA, Mertsoylu H, et al. The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol. International Journal of Immunopathology and Pharmacology. 2024;38. doi:10.1177/03946320241284089
BibTeX
@article{Topkan2024,
author = {Topkan, Erkan and Kilic Durankus, Nilufer and Senyurek, Sukran and Öztürk, Duriye and Besen, Ali Ayberk and Mertsoylu, Huseyin and Pehlivan, Berrin and Selek, Ugur},
title = {The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2024},
volume = {38},
doi = {10.1177/03946320241284089}
}
EUVIMED